Denali Therapeutics Inc. $DNLI Holdings Increased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 15.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,612 shares of the company’s stock after buying an additional 753 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Denali Therapeutics were worth $79,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in DNLI. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Denali Therapeutics by 88.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,766,916 shares of the company’s stock worth $91,996,000 after buying an additional 3,184,042 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Denali Therapeutics by 15.9% in the 1st quarter. Wellington Management Group LLP now owns 11,409,598 shares of the company’s stock worth $155,113,000 after purchasing an additional 1,561,647 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Denali Therapeutics by 42.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,367,234 shares of the company’s stock worth $59,373,000 after purchasing an additional 1,308,619 shares during the last quarter. Millennium Management LLC grew its stake in shares of Denali Therapeutics by 269.4% in the 1st quarter. Millennium Management LLC now owns 1,493,068 shares of the company’s stock worth $20,298,000 after purchasing an additional 1,088,844 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock worth $22,732,000 after purchasing an additional 614,555 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Stock Down 4.9%

DNLI stock opened at $15.37 on Monday. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $33.33. The company has a quick ratio of 10.27, a current ratio of 10.27 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -5.49 and a beta of 1.30. The company has a 50 day moving average of $14.60 and a two-hundred day moving average of $14.25.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.02. During the same quarter in the previous year, the company posted ($0.59) earnings per share. On average, equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on DNLI shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Denali Therapeutics in a research report on Monday, September 8th. TD Cowen raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Monday, July 28th. Morgan Stanley dropped their target price on shares of Denali Therapeutics from $33.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, August 18th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, October 8th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics has an average rating of “Buy” and an average target price of $33.50.

Insider Buying and Selling

In other Denali Therapeutics news, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the sale, the insider directly owned 217,391 shares in the company, valued at $2,952,169.78. The trade was a 1.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Alexander O. Schuth sold 2,937 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total transaction of $39,884.46. Following the completion of the sale, the insider owned 242,346 shares of the company’s stock, valued at $3,291,058.68. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 6,680 shares of company stock valued at $91,569 over the last quarter. Corporate insiders own 12.50% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.